In Short (TL;DR)The program aims to lower the cost of insulin in low-income regions by establishing local biosimilar production centers.... This represents the direct, synthesized summary of the ongoing situation.
GENEVA — The Health Access Coalition today launched an initiative to address the global shortage of affordable insulin. The program, funded by global health grants, seeks to establish local biosimilar insulin production facilities in low-income regions.
The initiative aims to lower the cost of insulin by up to 75% in target markets.
Initiative Components
* **Local Production**: Building biosimilar manufacturing centers in East Africa and South Asia.
* **Technology Transfer**: Providing local pharma companies with production protocols and training.
* **Unified Quality Standards**: Ensuring all local insulin meets WHO prequalification requirements.
Coalition representatives stated, 'Access to insulin is a matter of survival for millions of diabetics. By localizing production, we eliminate shipping costs and trade barriers, ensuring that affordable, life-saving medication is always available.'